bluebird bio (BLUE) Price Target Reduced to $149 at BofA/Merrill Lynch
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/12/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
bluebird bio to present LentiGlobin® BB305 Clinical Data and bb2121 Preclinical Data at Annual Meeting of the American Society of Hematology
November 5, 2015 8:00 AM ESTÂ Â Â Â Six abstracts accepted for presentation
Interim data on LentiGlobin in beta-thalassemia show six of six evaluable non-0/0 patients are transfusion-independent as of July 31st data cut-off; 0/0 patients have achieved varying degrees of transfusion reduction as of data cut-off
    Median production of corrected HbAT87Q globin: 5.2 g/dL among patients of all genotypes followed for at least six months in HGB-204 study, as of July 31st data cut-off
    Patient with sickle cell disease from HGB-205 study producing 51.5% anti-sickling... More
